Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 3, 2011, Pages 561-569

  Wirrig, Elaine E ^a   Hinton, Robert B ^a   Yutzey, Katherine E ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Aortic valve disease; Calcification; Extracellular matrix; Osteochondrogenic gene program; Valvular interstitial cells

Indexed keywords

CELL PROTEIN; COLLAGEN TYPE 10; COLLAGEN TYPE 2; HISTONE H3; PROTEIN MEF2C; PROTEIN TWIST1; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG;

ADULT; AGED; AORTA VALVE DISEASE; ARTICLE; BONE DEVELOPMENT; BONE TISSUE; CALCIFICATION; CARTILAGE; CELL ACTIVATION; CELL DIFFERENTIATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MESENCHYMAL STEM CELL; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SCHOOL CHILD; SIGNAL TRANSDUCTION;

AGED; AORTIC VALVE; BIOLOGICAL MARKERS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; CALCINOSIS; CARTILAGE; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CHILD; CHILD, PRESCHOOL; CHONDROGENESIS; COLLAGEN; CORE BINDING FACTOR ALPHA 1 SUBUNIT; EXTRACELLULAR MATRIX; HEART VALVE DISEASES; HUMANS; MADS DOMAIN PROTEINS; MESENCHYMAL STEM CELLS; MYOGENIC REGULATORY FACTORS; OSTEOGENESIS; TRANSCRIPTION FACTORS;

EID: 79551611520     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.12.005     Document Type: Article

References (52)

1. Bach D.S., Radeva J.I., Birnbaum H.G., Fournier A.A., Tuttle E.G. Prevalence, referral patterns, testing, and surgery in aortic valve disease: leaving women and elderly patients behind?. J. Heart Valve Dis. 2007, 16:362-369.
2. Nkomo V.T., Gardin J.M., Skelton T.N., Gottdiener J.S., Scott C.G., Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006, 368:1005-1011.
3. Bonow R.O., Carabello B.A., Chatterjee K., de Leon A.C., Faxon D.P., Freed M.D., et al. Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. Circulation 2008, 118:e523-e661.
4. Otto C.M. Valvular aortic stenosis: disease severity and timing of intervention. J. Am. Coll. Cardiol. 2006, 47:2141-2151.
5. Rajamannan N.M., Aikawa E., Grande-Allen K.J., Heistad D., Masters K.S., Mathieu P., et al. NHLBI Working Group: calcific aortic stenosis 2009 September, 21. http://wwwnhlbinihgov/meetings/workshops/cashtm.
6. Gallegos R.P. Selection of prosthetic heart valves. Curr Treat Options Cardiovasc Med. 2006, 8:443-452.
7. Keane J.F., Driscoll D.J., Gersony W.M., Hayes C.J., Kidd L., O'Fallon W.M., et al. Second natural history study of congenital heart defects. Results of treatment of patients with aortic valvar stenosis. Circulation 1993, 87(2 Suppl):I16-I27.
8. Combs M.D., Yutzey K.E. Heart valve development: regulatory networks in development and disease. Circ. Res. 2009, 105:408-421.
9. Lincoln J., Lange A.W., Yutzey K.E. Hearts and bones: shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development. Dev. Biol. 2006, 294:292-302.
10. Akiyama H., Chaboissier M.C., Martin J.F., Schedl A., de Crombrugghe B. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev. 2002, 16:2813-2828.
11. Bialek P., Kern B., Yang X., Schrock M., Sosic D., Hong N., et al. A twist code determines the onset of osteoblast differentiation. Dev. Cell 2004, 6:423-435.
12. Chakraborty S., Wirrig E.E., Hinton R.B., Merrill W.H., Spicer D.B., Yutzey K.E. Twist1 promotes heart valve cell proliferation and extracellular matrix gene expression during development in vivo and is expressed in human diseased aortic valves. Dev. Biol. 2010, 347:167-179.
13. Chen Y.H., Ishii M., Sucov H.M., Maxson R.E. Msx1 and Msx2 are required for endothelial-mesenchymal transformation of the atrioventricular cushions and patterning of the atrioventricular myocardium. BMC Dev. Biol. 2008, 8:75.
14. Lincoln J., Kist R., Scherer G., Yutzey K.E. Sox9 is required for precursor cell expansion and extracellular matrix organization during mouse heart valve development. Dev. Biol. 2007, 305:120-132.
15. Ma L., Lu M.F., Schwartz R.J., Martin J.F. Bmp2 is essential for cardiac cushion epithelial-mesenchymal transition and myocardial patterning. Development 2005, 132:5601-5611.
16. Satokata I., Ma L., Ohshima H., Bei M., Woo I., Nishizawa K., et al. Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat. Genet. 2000, 24:391-395.
17. Shelton E.L., Yutzey K.E. Twist1 function in endocardial cushion cell proliferation, migration, and differentiation during heart valve development. Dev. Biol. 2008, 317:282-295.
18. Yoon B.S., Ovchinnikov D.A., Yoshii I., Mishina Y., Behringer R.R., Lyons K.M. Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo. Proc. Natl Acad. Sci. USA 2005, 102:5062-5067.
19. Liu A.C., Joag V.R., Gotlieb A.I. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am. J. Pathol. 2007, 171:1407-1418.
20. Aikawa E., Whittaker P., Farber M., Mendelson K., Padera R.F., Aikawa M., et al. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation 2006, 113:1344-1352.
21. Hinton R.B., Lincoln J., Deutsch G.H., Osinska H., Manning P.B., Benson D.W., et al. Extracellular matrix remodeling and organization in developing and diseased aortic valves. Circ. Res. 2006, 98:1431-1438.
22. Caira F.C., Stock S.R., Gleason T.G., McGee E.C., Huang J., Bonow R.O., et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J. Am. Coll. Cardiol. 2006, 47:1707-1712.
23. Rabkin E., Aikawa M., Stone J.R., Fukumoto Y., Libby P., Schoen F.J. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 2001, 104:2525-2532.
24. Rabkin-Aikawa E., Farber M., Aikawa M., Schoen F.J. Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J. Heart Valve Dis. 2004, 13:841-847.
25. Bosse Y., Miqdad A., Fournier D., Pepin A., Pibarot P., Mathieu P. Refining molecular pathways leading to calcific aortic valve stenosis by studying gene expression profile of normal and calcified stenotic human aortic valves. Circ Cardiovasc Genet. 2009, 2:489-498.
26. Fondard O., Detaint D., Iung B., Choqueux C., Adle-Biassette H., Jarraya M., et al. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur. Heart J. 2005, 26:1333-1341.
27. Otto C.M., Kuusisto J., Reichenbach D.D., Gown A.M., O'Brien K.D. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994, 90:844-853.
28. Beppu S., Suzuki S., Matsuda H., Ohmori F., Nagata S., Miyatake K. Rapidity of progression of aortic stenosis in patients with congenital bicuspid aortic valves. Am. J. Cardiol. 1993, 71:322-327.
29. Roberts W.C. The congenitally bicuspid aortic valve. A study of 85 autopsy cases. Am. J. Cardiol. 1970, 26:72-83.
30. Ward C. Clinical significance of the bicuspid aortic valve. Heart 2000, 83:81-85.
31. Roberts W.C., Ko J.M. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation 2005, 111:920-925.
32. Rajamannan N.M., Subramaniam M., Rickard D., Stock S.R., Donovan J., Springett M., et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003, 107:2181-2184.
33. Alexopoulos A., Bravou V., Peroukides S., Kaklamanis L., Varakis J., Alexopoulos D., et al. Bone regulatory factors NFATc1 and Osterix in human calcific aortic valves. Int. J. Cardiol. 2010, 139:142-149.
34. Mohler E.R., Gannon F., Reynolds C., Zimmerman R., Keane M.G., Kaplan F.S. Bone formation and inflammation in cardiac valves. Circulation 2001, 103:1522-1528.
35. Snarr B.S., O'Neal J.L., Chintalapudi M.R., Wirrig E.E., Phelps A.L., Kubalak S.W., et al. Isl1 expression at the venous pole identifies a novel role for the second heart field in cardiac development. Circ. Res. 2007, 101:971-974.
36. Lin Q., Lu J., Yanagisawa H., Webb R., Lyons G.E., Richardson J.A., et al. Requirement of the MADS-box transcription factor MEF2C for vascular development. Development 1998, 125:4565-4574.
37. Lin Q., Schwarz J., Bucana C., Olson E.N. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 1997, 276:1404-1407.
38. Arnold M.A., Kim Y., Czubryt M.P., Phan D., McAnally J., Qi X., et al. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev. Cell 2007, 12:377-389.
39. von Bubnoff A., Cho K.W. Intracellular BMP signaling regulation in vertebrates: pathway or network?. Dev. Biol. 2001, 239:1-14.
40. Chakraborty S., Cheek J., Sakthivel B., Aronow B.J., Yutzey K.E. Shared gene expression profiles in developing heart valves and osteoblast progenitor cells. Physiol. Genomics 2008, 35:75-85.
41. Gress C.J., Jacenko O. Growth plate compressions and altered hematopoiesis in collagen X null mice. J. Cell Biol. 2000, 149:983-993.
42. Li S.W., Prockop D.J., Helminen H., Fassler R., Lapvetelainen T., Kiraly K., et al. Transgenic mice with targeted inactivation of the Col2 alpha 1 gene for collagen II develop a skeleton with membranous and periosteal bone but no endochondral bone. Genes Dev. 1995, 9:2821-2830.
43. Mead T.J., Yutzey K.E. Notch pathway regulation of chondrocyte differentiation and proliferation during appendicular and axial skeleton development. Proc. Natl Acad. Sci. USA 2009, 106:14420-14425.
44. Ng L.J., Tam P.P., Cheah K.S. Preferential expression of alternatively spliced mRNAs encoding type II procollagen with a cysteine-rich amino-propeptide in differentiating cartilage and nonchondrogenic tissues during early mouse development. Dev. Biol. 1993, 159:403-417.
45. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764.
46. Jian B., Narula N., Li Q.Y., Mohler E.R., Levy R.J. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg. 2003, 75:65-457. discussion 65-6.
47. Babu A.N., Meng X., Zou N., Yang X., Wang M., Song Y., et al. Lipopolysaccharide stimulation of human aortic valve interstitial cells activates inflammation and osteogenesis. Ann. Thorac. Surg. 2008, 86:71-76.
48. Hjortnaes J., Butcher J., Figueiredo J.L., Riccio M., Kohler R.H., Kozloff K.M., et al. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur. Heart J. 2010, 31:1975-1984.
49. Visconti R.P., Ebihara Y., LaRue A.C., Fleming P.A., McQuinn T.C., Masuya M., et al. An in vivo analysis of hematopoietic stem cell potential: hematopoietic origin of cardiac valve interstitial cells. Circ. Res. 2006, 98:690-696.
50. Miller J.D., Chu Y., Brooks R.M., Richenbacher W.E., Pena-Silva R., Heistad D.D. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J. Am. Coll. Cardiol. 2008, 52:843-850.
51. Osman L., Yacoub M.H., Latif N., Amrani M., Chester A.H. Role of human valve interstitial cells in valve calcification and their response to atorvastatin. Circulation 2006, 114(1 Suppl):I547-I552.
52. Yang X., Meng X., Su X., Mauchley D.C., Ao L., Cleveland J.C., et al. Bone morphogenic protein 2 induces Runx2 and osteopontin expression in human aortic valve interstitial cells: role of Smad1 and extracellular signal-regulated kinase 1/2. J. Thorac. Cardiovasc. Surg. 2009, 138:1008-1015.